Last reviewed · How we verify
Metformin Therapy
Metformin Therapy, developed by Temple University, is a marketed drug with a well-established presence in the treatment of diabetes. A key strength is the protection afforded by its composition patent, which is set to expire in 2028. The primary risk lies in the potential increase in competition following the patent expiry.
At a glance
| Generic name | Metformin Therapy |
|---|---|
| Also known as | Metformin |
| Sponsor | Temple University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion (PHASE2)
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- Diabetes Management for Primary Healthcare Centers. (NA)
- Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2)
- Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function (PHASE2)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Surgical or Medical Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin Therapy CI brief — competitive landscape report
- Metformin Therapy updates RSS · CI watch RSS
- Temple University portfolio CI